335 related articles for article (PubMed ID: 34485599)
1. A consolidated AAV system for single-cut CRISPR correction of a common Duchenne muscular dystrophy mutation.
Zhang Y; Nishiyama T; Li H; Huang J; Atmanli A; Sanchez-Ortiz E; Wang Z; Mireault AA; Mammen PPA; Bassel-Duby R; Olson EN
Mol Ther Methods Clin Dev; 2021 Sep; 22():122-132. PubMed ID: 34485599
[TBL] [Abstract][Full Text] [Related]
2. A humanized knockin mouse model of Duchenne muscular dystrophy and its correction by CRISPR-Cas9 therapeutic gene editing.
Zhang Y; Li H; Nishiyama T; McAnally JR; Sanchez-Ortiz E; Huang J; Mammen PPA; Bassel-Duby R; Olson EN
Mol Ther Nucleic Acids; 2022 Sep; 29():525-537. PubMed ID: 36035749
[TBL] [Abstract][Full Text] [Related]
3. Correction of Three Prominent Mutations in Mouse and Human Models of Duchenne Muscular Dystrophy by Single-Cut Genome Editing.
Min YL; Chemello F; Li H; Rodriguez-Caycedo C; Sanchez-Ortiz E; Mireault AA; McAnally JR; Shelton JM; Zhang Y; Bassel-Duby R; Olson EN
Mol Ther; 2020 Sep; 28(9):2044-2055. PubMed ID: 32892813
[TBL] [Abstract][Full Text] [Related]
4. Enhanced CRISPR-Cas9 correction of Duchenne muscular dystrophy in mice by a self-complementary AAV delivery system.
Zhang Y; Li H; Min YL; Sanchez-Ortiz E; Huang J; Mireault AA; Shelton JM; Kim J; Mammen PPA; Bassel-Duby R; Olson EN
Sci Adv; 2020 Feb; 6(8):eaay6812. PubMed ID: 32128412
[TBL] [Abstract][Full Text] [Related]
5. Single-swap editing for the correction of common Duchenne muscular dystrophy mutations.
Chai AC; Chemello F; Li H; Nishiyama T; Chen K; Zhang Y; Sánchez-Ortiz E; Alomar A; Xu L; Liu N; Bassel-Duby R; Olson EN
Mol Ther Nucleic Acids; 2023 Jun; 32():522-535. PubMed ID: 37215149
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic Applications of CRISPR/Cas for Duchenne Muscular Dystrophy.
Wong TWY; Cohn RD
Curr Gene Ther; 2017; 17(4):301-308. PubMed ID: 29173172
[TBL] [Abstract][Full Text] [Related]
7. CRISPR-Cas9 Correction of Duchenne Muscular Dystrophy in Mice by a Self-Complementary AAV Delivery System.
Zhang Y; Bassel-Duby R; Olson EN
Methods Mol Biol; 2023; 2587():411-425. PubMed ID: 36401041
[TBL] [Abstract][Full Text] [Related]
8. Gene editing of Duchenne muscular dystrophy using biomineralization-based spCas9 variant nanoparticles.
Li S; Du M; Deng J; Deng G; Li J; Song Z; Han H
Acta Biomater; 2022 Dec; 154():597-607. PubMed ID: 36243370
[TBL] [Abstract][Full Text] [Related]
9. Prevention of early-onset cardiomyopathy in
Rok M; Wong TWY; Maino E; Ahmed A; Yang G; Hyatt E; Lindsay K; Fatehi S; Marks R; Delgado-Olguín P; Ivakine EA; Cohn RD
Mol Ther Methods Clin Dev; 2023 Sep; 30():246-258. PubMed ID: 37545481
[TBL] [Abstract][Full Text] [Related]
10. Molecular correction of Duchenne muscular dystrophy by splice modulation and gene editing.
Hanson B; Wood MJA; Roberts TC
RNA Biol; 2021 Jul; 18(7):1048-1062. PubMed ID: 33472516
[TBL] [Abstract][Full Text] [Related]
11. Targeting Duchenne muscular dystrophy by skipping DMD exon 45 with base editors.
Gapinske M; Winter J; Swami D; Gapinske L; Woods WS; Shirguppe S; Miskalis A; Busza A; Joulani D; Kao CJ; Kostan K; Bigot A; Bashir R; Perez-Pinera P
Mol Ther Nucleic Acids; 2023 Sep; 33():572-586. PubMed ID: 37637209
[TBL] [Abstract][Full Text] [Related]
12. Precise correction of Duchenne muscular dystrophy exon deletion mutations by base and prime editing.
Chemello F; Chai AC; Li H; Rodriguez-Caycedo C; Sanchez-Ortiz E; Atmanli A; Mireault AA; Liu N; Bassel-Duby R; Olson EN
Sci Adv; 2021 Apr; 7(18):. PubMed ID: 33931459
[TBL] [Abstract][Full Text] [Related]
13. CRISPR-Cas9 corrects Duchenne muscular dystrophy exon 44 deletion mutations in mice and human cells.
Min YL; Li H; Rodriguez-Caycedo C; Mireault AA; Huang J; Shelton JM; McAnally JR; Amoasii L; Mammen PPA; Bassel-Duby R; Olson EN
Sci Adv; 2019 Mar; 5(3):eaav4324. PubMed ID: 30854433
[TBL] [Abstract][Full Text] [Related]
14. Single-cut genome editing restores dystrophin expression in a new mouse model of muscular dystrophy.
Amoasii L; Long C; Li H; Mireault AA; Shelton JM; Sanchez-Ortiz E; McAnally JR; Bhattacharyya S; Schmidt F; Grimm D; Hauschka SD; Bassel-Duby R; Olson EN
Sci Transl Med; 2017 Nov; 9(418):. PubMed ID: 29187645
[TBL] [Abstract][Full Text] [Related]
15. Gene modification strategies using AO-mediated exon skipping and CRISPR/Cas9 as potential therapies for Duchenne muscular dystrophy patients.
Solberg MH; Shariatzadeh M; Wilson SL
Eng Biol; 2020 Dec; 4(3):37-42. PubMed ID: 36968157
[TBL] [Abstract][Full Text] [Related]
16. The AAV-mediated and RNA-guided CRISPR/Cas9 system for gene therapy of DMD and BMD.
Wang JZ; Wu P; Shi ZM; Xu YL; Liu ZJ
Brain Dev; 2017 Aug; 39(7):547-556. PubMed ID: 28390761
[TBL] [Abstract][Full Text] [Related]
17. Functional Rescue of Dystrophin Deficiency in Mice Caused by Frameshift Mutations Using Campylobacter jejuni Cas9.
Koo T; Lu-Nguyen NB; Malerba A; Kim E; Kim D; Cappellari O; Cho HY; Dickson G; Popplewell L; Kim JS
Mol Ther; 2018 Jun; 26(6):1529-1538. PubMed ID: 29730196
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic Exon Skipping Through a CRISPR-Guided Cytidine Deaminase Rescues Dystrophic Cardiomyopathy in Vivo.
Li J; Wang K; Zhang Y; Qi T; Yuan J; Zhang L; Qiu H; Wang J; Yang HT; Dai Y; Song Y; Chang X
Circulation; 2021 Nov; 144(22):1760-1776. PubMed ID: 34698513
[TBL] [Abstract][Full Text] [Related]
19. Long-term maintenance of dystrophin expression and resistance to injury of skeletal muscle in gene edited DMD mice.
Karri DR; Zhang Y; Chemello F; Min YL; Huang J; Kim J; Mammen PPA; Xu L; Liu N; Bassel-Duby R; Olson EN
Mol Ther Nucleic Acids; 2022 Jun; 28():154-167. PubMed ID: 35402069
[TBL] [Abstract][Full Text] [Related]
20. New advancements in CRISPR based gene therapy of Duchenne muscular dystrophy.
Eslahi A; Alizadeh F; Avan A; Ferns GA; Moghbeli M; Reza Abbaszadegan M; Mojarrad M
Gene; 2023 May; 867():147358. PubMed ID: 36914142
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
